• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO LS™* & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO LS™* & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Strong cash flow despite the influence of Covid-19

FIRST QUARTER 2020 (JAN – MAR)
  • Total net sales (incl. durable goods) in the quarter amounted to SEK 46.5 (47.7) million, corresponding to a decrease of 3 percent in SEK and 6 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 44.2 (46.8) million, corresponding to a decrease of 6 percent in SEK and 9 percent in local currency.
  • Sales from warm perfusion represented 27 percent (43) of sales of non-durable goods. Sales of warm perfusion products were affected in March partly due to fewer EVLP:s being performed and partly because some orders were not delivered to the clinics when they only received Covid-19 related products.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 7.6 million (3.2), corresponding to an EBITDA margin of 16 percent (7). Operating income in the first quarter was positively affected by the resolution of cost provisions of SEK 2.5 million (-5.5) related to the Group's share-based bonus program for employees outside Sweden. Adjusted for this provision, EBITDA for the first quarter amounted to SEK 5.1 million (8.8), corresponding to an EBITDA margin of 11 percent (18).
  • Operating income amounted to SEK 0 million (-1.9), after amortization and depreciation of SEK 7.5 (5.1) million. Operating income adjusted for the share-based bonus program was SEK -2.5 million (3.7).
  • Net income amounted to SEK 6.5 (-0.3) million, resulting in earnings per share of SEK 0.25 SEK (-0.01).
  • Cash flow from operating activities during the quarter amounted to SEK 9.2 (0.1) million. Cash flow from investing activities amounted to SEK -15.9 (-11.7) million. Cash position at the end of the quarter amounted to SEK 158.7 million, a decrease of SEK 1.3 million compared to the beginning of the year.
  • The further developed, and more user-friendly, Perfadex® Plus with Click port was launched worldwide.
  • For the first time, an XPS™ was delivered to a paediatric (children) hospital in Rome, Italy. At the end of the period 52 clinics had access to either XPS™ or LS™.
  • The company's studies for PrimECC® and Cardiac preservation prior to transplantation in Europe are ready to include the first patients. These two studies have not been able to start during the first quarter, due to the fact that clinics in Europe temporarily have paused all clinical trials during the Covid-19 epidemic.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 11.30 a.m. CET on Thursday, April 9, 2020. Telephone UK: +44 333 300 0804 or USA: +1 855 85 70686. PIN: 52504358#

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.  The information was submitted for publication, through the agency of the contact person set out above, at 07:30 am CET on April 9, 2020. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

Newsletter

I have read and accepted XVIVO's Privacy policy

*By signing up to our newsletter you consent to XVIVO sending you our insights newsletter and occasional additional communications. Your personal data will be transfered to a third party newsletter distributor engaged by XVIVO. All processing of your personal data is in compliance with the XVIVO Privacy Policy. For more information on how we use your personal data, please read XVIVO’s Privacy policy

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2022 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve